OncoTargets and Therapy is an international, peer-reviewed journal focusing on molecular aspects of cancer research, that is, the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer.

The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype.

Specific topics covered by the journal include:

-Novel therapeutic targets and innovative agents

-Novel therapeutic regimens for improved benefit and/or decreased side effects

-Early stage clinical trials

Further considerations when submitting to OncoTargets and Therapy:

-Studies containing in vivo animal model data will be considered favorably.

-Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines.

-Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples.

-Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.

-Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.

-Single nucleotide polymorphism (SNP) studies will not be considered.

《Oncotargets And Therapy》是一本由DOVE MEDICAL PRESS LTD出版商出版的专业医学期刊，该刊创刊于2008年，刊期1 issue/year，该刊已被国际权威数据库SCIE收录。在中科院最新升级版分区表中，该刊分区信息为大类学科：医学 4区，小类学科：生物工程与应用微生物 3区；肿瘤学 4区；在JCR（Journal Citation Reports）分区等级为Q2。该刊发文范围涵盖生物工程与应用微生物等领域，旨在及时、准确、全面地报道国内外生物工程与应用微生物工作者在该领域取得的最新研究成果、工作进展及学术动态、技术革新等，促进学术交流，鼓励学术创新。2021年影响因子为4.345，平均审稿速度较慢,6-12周。